LGVN

LGVN

Longeveron LLC

Net โ€”top 1%Rev โ€”top 1%5Y
Hold

Longeveron develops cellular therapies targeting aging-related and life-threatening conditions. Its main product, LOMECEL-B, is an allogeneic mesenchymal stem cell therapy in clinical trials for conditions like hypoplastic left heart syndrome and Alzheimer's disease.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$14today

Score Overview

1 Year
Score
Net Growth-42.14%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-49.87%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growthโ€”
Net Trendโ€”
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trendโ€”
Revenue Consistencyโ€”
All Time
Score
Net Growth-33.20%
Net Trend25%
Net Income Consistency
Rev Growth-8.19%
Rev Trend25%
Revenue Consistency

See the full market ranking โ†’

Longeveron LLC fundamental performance

Across Longeveron LLC's full reported history, from 2021 to 2025, revenue declined from $ 1M to $ 1M and net income went from -$ 17M to -$ 22M. Revenue increased in 25% of the years measured; net income in 25%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.75โ€”
1 Year2025-08-12
$ 0.689.68%
5 Years2021-08-12
$ 54.10-98.62%
All Time2021-02-12
$ 74.10-98.99%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 1M-$ 22M$ 4M
2024$ 2M-$ 15M$ 19M
2023$ 709K-$ 21M$ 5M
2022$ 1M-$ 18M$ 19M
IPO2021$ 1M-$ 17M$ 35M

Explore beyond LGVN

You're looking at Longeveron LLC. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies